Good info, thanks. So depending on how much of that was milestone payments probably somewhere in the 15-20% area. In that case the terms on the BioNtech deal would be stellar for IPIX. Even if therapeutics are 10% of the Pfizer vaccine, $50M/quarter would be a massively funded company ready to develop several other indications in parallel.